Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEUK203-13 in Advanced SCLC and Neuroendocrine Tumors
NCT07366658Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2026
- Primary completion
- Oct 2026
- Modality
- Patient-derived iPSCs, Lymphokine-Activated Killer Cells, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NEUK203-13 in small cell lung cancer (SCLC) and Neuroendocrine Neoplasm (NEN), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Adverse Events at 12 months. Started Feb 2026; status: recruiting.
02
Drugs
NEUK203-13
03
Conditions
small cell lung cancer (SCLC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT07366658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07366658.